New oral drug trial offers hope for Tough-to-Treat cancers
NCT ID NCT05988918
Summary
This study is testing an experimental oral medication called ESK981 for people with advanced pancreatic cancer and certain neuroendocrine cancers that have stopped responding to standard treatments. The trial will enroll 66 patients across three groups to see if taking ESK981 on a 5-days-on, 2-days-off schedule can help control cancer growth and extend the time before the disease worsens. Researchers will monitor how long patients live without their cancer progressing, track tumor responses, and carefully record any side effects.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PANCREATIC ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Barbara Ann Karmanos Cancer Institute
RECRUITINGDetroit, Michigan, 48201, United States
Contact
Contact
-
Rogel Cancer Center
RECRUITINGAnn Arbor, Michigan, 48109, United States
Contact Phone: •••-•••-••••
Contact
-
University of Wisconsin Carbone Cancer Center
RECRUITINGMadison, Wisconsin, 53792, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Conditions
Explore the condition pages connected to this study.